open access

Vol 15, No 1 (2018)
Case report
Published online: 2018-03-28
Get Citation

Dependence on extremely high dose of zolpidem — case report and data review

Wiktor Dróżdż, Magdalena Skibicka, Danuta Piątkiewicz, Maciej Piątkowski
Psychiatria 2018;15(1):13-25.

open access

Vol 15, No 1 (2018)
Prace kazuistyczne
Published online: 2018-03-28

Abstract

The case of a physician addicted to extremely high dose of zolpidem is reported. She was admitted to psychiatric ward also
due to codeine and caffeine abuse. As a result of complicated abstinence syndrome she was hospitalised for long time. Specific
clinical and treatment problems associated with abandonment of high-dose zolpidem were discussed. Additionally, current
data on many potentially serious consequences of zolpidem abuse were presented of which physicians who prescribe this
medication should be aware.

Abstract

The case of a physician addicted to extremely high dose of zolpidem is reported. She was admitted to psychiatric ward also
due to codeine and caffeine abuse. As a result of complicated abstinence syndrome she was hospitalised for long time. Specific
clinical and treatment problems associated with abandonment of high-dose zolpidem were discussed. Additionally, current
data on many potentially serious consequences of zolpidem abuse were presented of which physicians who prescribe this
medication should be aware.

Get Citation

Keywords

zolpidem, addiction, abstinence syndrome, complications

About this article
Title

Dependence on extremely high dose of zolpidem — case report and data review

Journal

Psychiatria (Psychiatry)

Issue

Vol 15, No 1 (2018)

Article type

Case report

Pages

13-25

Published online

2018-03-28

Bibliographic record

Psychiatria 2018;15(1):13-25.

Keywords

zolpidem
addiction
abstinence syndrome
complications

Authors

Wiktor Dróżdż
Magdalena Skibicka
Danuta Piątkiewicz
Maciej Piątkowski

References (45)
  1. Fitzgerald AC, Wright BT, Heldt SA. The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors. Psychopharmacology (Berl). 2014; 231(9): 1865–1896.
  2. Jembrek MJ, Vlainić J, Šuran J. Zolpidem withdrawal induced uncoupling of GABA(A) receptors in vitro associated with altered GABA(A) receptor subunit mRNA expression. Acta Neurobiol Exp (Wars). 2015; 75(2): 160–171.
  3. Hoffmann F, Pfannkuche M, Glaeske G. [High usage of zolpidem and zopiclone. Cross-sectional study using claims data]. Nervenarzt. 2008; 79(1): 67–72.
  4. Wainstein L, Victorri-Vigneau C, Sébille V, et al. Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis. Int Clin Psychopharmacol. 2011; 26(1): 54–62.
  5. Gołda A, Dymek J, Dziwisz K, et al. Legalni użytkownicy nierefundowanych leków psychotropowych w sce – badanie pilotażowe. Farm Pol. 2014; 70(12): 665–674.
  6. Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007; 64(2): 198–209.
  7. Liappas IA, Malitas PN, Dimopoulos NP, et al. Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. J Psychopharmacol. 2003; 17(1): 131–135.
  8. Jamroży A, Habrat B, Basińska-Starzycka A. Uzależnienie od niebenzodiazepinowych leków nasennych: opis dziesięciu przypadków. Alkoholizm i Narkomania. 2009; 22(1): 87–105.
  9. Cubała WJ. Czynniki wpływające na ryzyko wystąpienia działań niepożądanych w trakcie leczenia zolpidemem. Psychiatria. 2007; 4(3): 124–127.
  10. Cubała WJ, Landowski J, Wichowicz HM. Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. Br J Clin Pharmacol. 2008; 65(3): 444–445.
  11. Olubodun JO, Ochs HR, Trüten V, et al. Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol. 2002; 42(10): 1142–1146.
  12. Hajak G, Müller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003; 98(10): 1371–1378.
  13. Shukla L, Bokka S, Shukla T, et al. Benzodiazepine and "Z-Drug" Dependence: Data From a Tertiary Care Center. Prim Care Companion CNS Disord. 2017; 19(1).
  14. McBeth BD, McNamara RM, Ankel FK, et al. Modafinil and zolpidem use by emergency medicine residents. Acad Emerg Med. 2009; 16(12): 1311–1317.
  15. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol. 2002; 451(2): 103–110.
  16. Kralic JE, O'Buckley TK, Khisti RT, et al. GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology. 2002; 43(4): 685–694.
  17. Chattopadhyay AC, Shukla L, Kandasamy A, et al. High-dose zolpidem dependence - Psychostimulant effects? A case report and literature review. Ind Psychiatry J. 2016; 25(2): 222–224.
  18. Boulanger-Rostowsky L, Fayet H, Benmoussa N, et al. [Dependence on zolpidem: a report of two cases]. Encephale. 2004; 30(2): 153–155.
  19. Huang MC, Lin HY, Chen CH. Dependence on zolpidem. Psychiatry Clin Neurosci. 2007; 61(2): 207–208.
  20. Cubała WJ, Wichowicz HM. Dependence on zolpidem: is pharmacokinetics important? Psychiatry Clin Neurosci. 2008; 62(1): 127.
  21. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008; 9(4): 310–322.
  22. Sun Yu, Lin CC, Lu CJ, et al. Association Between Zolpidem and Suicide: A Nationwide Population-Based Case-Control Study. Mayo Clin Proc. 2016; 91(3): 308–315.
  23. Huang WS, Tsai CH, Lin CC, et al. Relationship between zolpidem use and stroke risk: a Taiwanese population-based case-control study. J Clin Psychiatry. 2013; 74(5): e433–e438.
  24. Huang HC, Tsai CH, Muo CH, et al. Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study. J Clin Psychiatry. 2015; 76(1): e104–e110.
  25. Lai SW. Risks and benefits of zolpidem use in Taiwan: a narrative review. Biomedicine (Taipei). 2016; 6(2): 8.
  26. Kao CH, Sun LM, Liang JA. Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study. Mayo Clin Proc. 2012; 87(5): 430–436.
  27. Lai MM, Lin CC, Lin CC, et al. Long-term use of zolpidem increases the risk of major injury: a population-based cohort study. Mayo Clin Proc. 2014; 89(5): 589–594.
  28. Ho YH, Chang YC, Huang WC, et al. Association between zolpidem use and glaucoma risk: a Taiwanese population-based case-control study. J Epidemiol. 2014 [Epub ahead of print]; 25(1)–19.
  29. Orriols L, Philip P, Moore N, et al. CESIR Research Group. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011; 89(4): 595–601.
  30. Wang LH, Lin HC, Lin CC, et al. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin Pharmacol Ther. 2010; 88(3): 369–374.
  31. Lai SW, Lin CL, Liao KF. Increased relative risk of acute pancreatitis in zolpidem users. Psychopharmacology (Berl). 2015; 232(12): 2043–2048.
  32. Chen SC, Chen HC, Liao SC, et al. Detoxification of high-dose zolpidem using cross-titration with an adequate equivalent dose of diazepam. Gen Hosp Psychiatry. 2012; 34(2): 210.e5–210.e7.
  33. Fernandes WH, Pereira YD, O' Tereza S. A case of Zolpidem dependence successfully detoxified with gabapentin. Indian J Psychiatry. 2013; 55(3): 290–292.
  34. Oulis P, Nakkas G, Masdrakis VG. Pregabalin in zolpidem dependence and withdrawal. Clin Neuropharmacol. 2011; 34(2): 90–91.
  35. Quaglio G, Faccini M, Vigneau CV, et al. Megadose bromazepam and zolpidem dependence: two case reports of treatment with flumazenil and valproate. Subst Abus. 2012; 33(2): 195–198.
  36. Quaglio G, Lugoboni F, Fornasiero A, et al. Dependence on zolpidem: two case reports of detoxification with flumazenil infusion. Int Clin Psychopharmacol. 2005; 20(5): 285–287.
  37. Jana AK, Arora M, Khess CRJ, et al. A case of zolpidem dependence successfully detoxified with clonazepam. Am J Addict. 2008; 17(4): 343–344.
  38. Liappas IA, Malitas PN, Dimopoulos NP, et al. Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis. World J Biol Psychiatry. 2003; 4(2): 93–96.
  39. Mariani JJ, Levin FR. Quetiapine treatment of zolpidem dependence. Am J Addict. 2007; 16(5): 426.
  40. Lin SK. Rapid detoxification of benzodiazepine or Z-drugs dependence using acetylcholinesterase inhibitors. Med Hypotheses. 2014; 83(1): 108–110.
  41. Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neuropharmacol. 2000; 23(5): 281–283.
  42. Tripodianakis J, Potagas C, Papageorgiou P, et al. Zolpidem-related epileptic seizures: a case report. Eur Psychiatry. 2003; 18(3): 140–141.
  43. Cubała WJ, Landowski J. Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(2): 539–540.
  44. Liappas IA, Papageorgiou CC, Rabavilas AD. Abnormal auditory N400 in a case of zolpidem dependence, during a working memory test. Eur Psychiatry. 2006; 21(2): 135–137.
  45. Stanton J, Randal P. Developing a psychiatrist-patient relationship when both people are doctors: a qualitative study. BMJ Open. 2016; 6(5): e010216.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl